secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAIA Biotechnology, Inc. (MAIA)
CIK:        0001878313
Form:       8-K
Filed at:   2025-06-24T23:59:59+00:00
Accession:  0001641172-25-016235
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MAIA appoints HCC specialists to SAB; Phase 2 trial enrollment expected by year-end 2025
--------------------------------------------------------------------------------

- Appointed Drs. Claudia Fulgenzi and David J. Pinato to SAB; both are HCC clinician-scientists.
- Planning Phase 2 trial of ateganosine (THIO) plus checkpoint inhibitor in hepatocellular carcinoma (HCC).
- Expects to begin enrolling HCC trial patients by end of 2025 upon obtaining regulatory approvals.
- FDA granted Orphan Drug Designation for ateganosine in HCC in 2022, potentially 7-year market exclusivity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1878313/000164117225016235/0001641172-25-016235-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1878313/000164117225016235/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-016235

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer